Novartis(US:NVS)2025-10-27 10:06Acquisition Details - Novartis has agreed to acquire Avidity Biosciences for a total consideration of USD 12 billion in cash, representing a premium of 46% to Avidity's closing share price on October 24, 2025[7][10]. - The merger is expected to close in the first half of 2026, subject to customary closing conditions and regulatory approvals[12]. - Avidity will separate its early-stage precision cardiology programs into a new company ("SpinCo") prior to the closing of the acquisition[7][11]. - The deal has been unanimously approved by the Boards of Directors of both companies, indicating strong support for the transaction[10]. Growth Opportunities - The acquisition is expected to raise Novartis's projected sales CAGR from +5% to +6% for the period 2024-2029, indicating a significant growth opportunity[6][7]. - The transaction is anticipated to unlock multi-billion-dollar opportunities with planned product launches before 2030[7]. Pipeline Enhancement - Avidity's late-stage neuroscience programs will enhance Novartis's pipeline, focusing on genetic neuromuscular diseases such as myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy[8][9]. - Novartis aims to leverage Avidity's Antibody Oligonucleotide Conjugates (AOCs™) platform to deliver targeted RNA therapeutics to muscle tissue[5][9]. - The acquisition aligns with Novartis's long-term neuroscience strategy, expanding its capabilities in treating serious genetic disorders[8]. Therapeutic Potential - Avidity's platform is designed to achieve targeted delivery of RNA therapeutics, potentially restoring muscle function and slowing disease progression[9][14].